Last $22.49 USD
Change Today +0.66 / 3.02%
Volume 80.9K
OMER On Other Exchanges
Symbol
Exchange
NASDAQ GM
Berlin
As of 10:09 AM 11/26/14 All times are local (Market data is delayed by at least 15 minutes).

omeros corp (OMER) Snapshot

Open
$21.84
Previous Close
$21.83
Day High
$22.75
Day Low
$21.61
52 Week High
11/26/14 - $22.75
52 Week Low
12/11/13 - $7.00
Market Cap
767.0M
Average Volume 10 Days
539.0K
EPS TTM
$-1.94
Shares Outstanding
34.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for OMEROS CORP (OMER)

omeros corp (OMER) Related Bloomberg News

View More Bloomberg News

omeros corp (OMER) Related Businessweek News

No Related Businessweek News Found

omeros corp (OMER) Details

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes products targeting inflammation, coagulopathies, and disorders of the central nervous system. Its clinical products include Omidria, which has completed two Phase III clinical trials for use during intraocular lens replacement, including cataract and other lens replacement surgery; OMS103 that is in Phase III clinical program for use during arthroscopic procedures, such as partial meniscectomy surgery; and OMS824, which is in Phase II clinical trial for the treatment of CNS disorders comprising schizophrenia and Huntington's disease. Its clinical programs also consist of OMS721 that is in Phase II clinical trial for the treatment of various complement-related diseases and disorders, including thrombotic microangiopathies; OMS405, which is in Phase II clinical trial for the treatment and prevention of addiction to substances of abuse; and OMS201 that has completed Phase 1/Phase 2 clinical trial for use during urological procedures, such as ureterscopy for removal of ureteral or renal stones. The company’s preclinical products and development programs comprise OMS527 for the treatment of addiction and compulsive disorders, as well as for movement disorders, such as Parkinson's disease; and OMS616 for the control of blood loss during surgery, or resulting from trauma or other hyperfibrinolytic conditions. Its preclinical products also include G protein-coupled receptors platform for multiple disorders across therapeutic area; GPR17 for demyelinating disorders; and antibody platform for the discovery of monoclonal antibodies. Omeros Corporation was incorporated in 1994 and is based in Seattle, Washington.

75 Employees
Last Reported Date: 03/13/14
Founded in 1994

omeros corp (OMER) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: $664.6K
Principal Financial Officer, Chief Accounting...
Total Annual Compensation: $79.7K
Vice President of Patent, General Counsel and...
Total Annual Compensation: $342.5K
Compensation as of Fiscal Year 2013.

omeros corp (OMER) Key Developments

Omeros Corporation Announces Positive Data Using OMS721

Omeros Corporation announced positive data using OMS721, the lead human monoclonal antibody for its mannan-binding lectin-associated serine protease-2 (MASP-2) program, to inhibit thrombus formation in an ex vivo pathophysiologic system of human atypical hemolytic uremic syndrome (aHUS), a form of thrombotic microangiopathy (TMA). TMAs are a family of rare, debilitating and life-threatening disorders characterized by excessive thrombi (clots) in the microcirculation of the body's organs, most commonly the kidney and brain. OMS721 is currently in a Phase 2 clinical program evaluating the drug's efficacy in treating TMAs, including aHUS. The data announced resulted from studies in a well-established experimental model of TMA aimed at assessing the potential therapeutic benefits of OMS721 in TMA using serum samples from aHUS patients with different etiologies obtained during the acute phase of disease as well as during remission. The experimental model is based on the finding that sera from aHUS patients promote the formation of thrombi on human microvascular endothelial cells, the defining pathological feature of TMA. The studies reported showed that OMS721 significantly inhibited thrombus formation when added to serum samples from aHUS patients obtained during the acute phase of disease (p<0.01) as well as during remission (p<0.0001). OMS721 was as effective at inhibiting thrombus formation as the positive control in the studies - soluble complement receptor 1, an agent that completely blocks the complement system. Omeros reported that OMS721 also significantly inhibited complement deposition compared to control treatment in an experimental ex vivo pathophysiologic system of complement activation in TMA, again using serum samples from aHUS patients obtained during the acute phase of disease (p<0.01) and during remission (p<0.001). Having demonstrated that the lectin pathway, and MASP-2 specifically, are involved in the pathophysiology of aHUS, Prof. Remuzzi and his team are currently conducting additional experiments to understand the mechanism by which OMS721 blocks ex vivo thrombus formation in aHUS and its effect on endothelial cells, platelets and the alternative pathway of complement.

Omeros Corporation Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Omeros Corporation reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported revenue of USD 0.214 million compared to USD 0.196 million a year ago. Loss from operations was USD 17.132 million compared to USD 13.434 million a year ago. Net loss was USD 18.327 million compared to USD 13.870 million a year ago. Basic and diluted net loss per share was USD 0.54 compared to USD 0.46 a year ago. For the nine months, the company reported revenue of USD 0.359 million compared to USD 1.431 million a year ago. Loss from operations was USD 50.033 million compared to USD 36.614 million a year ago. Net loss was USD 52.960 million compared to USD 37.951 million a year ago. Basic and diluted net loss per share was USD 1.61 compared to USD 1.36 a year ago.

Omeros Corporation Announces Positive Data Using Derivative of OMS721 in Animal Model of Stroke

Omeros Corporation announced positive data using a derivative of OMS721 in animal model of stroke. OMS721 is the company's lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2). MASP-2 is critical to the function of the lectin pathway, one of the principal components of the complement system, a key part of the immune response. Omeros controls the worldwide rights to MASP-2 inhibition and to all therapeutics targeting MASP-2. The study evaluated the effect of MASP-2 blockade on neurological deficits and the size of brain infarcts 48 hours after induction of an ischemic stroke. Compared to control antibody-treated mice, mice treated with MASP-2 antibody demonstrated significantly reduced neurological deficits 48 hours after an ischemic stroke. In addition, the infarcted area of the brain was significantly smaller in MASP-2 antibody-treated mice. A similar degree of protection was also observed in gene-targeted MASP-2-deficient mice, which showed significantly lesser neurological deficits and infarct sizes compared to wild-type control mice. OMS721 is currently being evaluated in a Phase 2 clinical trial in patients with complement-mediated thrombotic microangiopathies (TMAs), including atypical hemolytic uremic syndrome (aHUS), thrombotic thrombocytopenic purpura (TTP), and stem cell transplant-related TMAs. Thrombotic microangiopathies are a family of rare, debilitating and life-threatening disorders characterized by multiple thrombi (clots) in the microcirculation of the body's organs, most commonly the kidney and brain. Omeros expects to be able to release data later this month on the effect of OMS721 on thrombus formation in a human ex vivo pathophysiologic system of aHUS using serum from aHUS patients both in the acute phase and in remission.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OMER:US $22.49 USD +0.66

OMER Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OMER.
View Industry Companies
 

Industry Analysis

OMER

Industry Average

Valuation OMER Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1,335.8x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 1,235.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OMEROS CORP, please visit www.omeros.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.